Usual	JJ	O
adult	NN	WHO
dose	VBD	O
4	CD	DOS
-	:	O
8	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

One	CD	DOS
or	CC	O
two	CD	DOS
capsules	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
dosage	NN	O
regimen	NNS	O
for	IN	O
TriNessa®	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
facial	JJ	O
acne	NN	O
,	,	O
as	IN	O
available	JJ	O
in	IN	O
a	DT	O
blister	NN	O
card	NN	O
with	IN	O
a	DT	O
tablet	NN	O
dispenser	NN	O
,	,	O
utilizes	VBZ	O
a	DT	O
21	CD	O
-	:	O
day	NN	O
active	JJ	O
and	CC	O
a	DT	O
7	CD	O
-	:	O
day	NN	O
placebo	NN	O
schedule	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
by	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
Weeks	NNP	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
4	CD	O
followed	VBN	O
by	IN	O
300	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
hypotension	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
CLEOCIN	NNP	UNIT
Vaginal	NNP	UNIT
Ovule	NNP	UNIT
(	(	O
containing	VBG	O
clindamycin	NN	O
phosphate	NN	O
equivalent	NN	O
to	TO	O
100	CD	DOS
mg	NNS	UNIT
clindamycin	VBP	O
per	IN	O
2.5	CD	DOS
g	JJ	UNIT
suppository	NN	O
)	)	O
intravaginally	RB	O
per	IN	FREQ
day	NN	FREQ
,	,	O
preferably	RB	O
at	IN	O
bedtime	NN	O
,	,	O
for	IN	O
3	CD	DUR
consecutive	JJ	DUR
days	NNS	DUR
.	.	O

Based	VBN	O
on	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
the	DT	O
average	JJ	O
prescribed	JJ	O
adult	JJ	WHO
daily	JJ	FREQ
dose	NN	O
of	IN	O
sevelamer	JJ	O
carbonate	NN	O
is	VBZ	O
approximately	RB	O
7.2	CD	DOS
g	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
prednisolone	NN	O
sodium	NN	O
(	(	O
prednisolone	JJ	O
sodium	NN	O
phosphate	NN	O
oral	JJ	O
solution	NN	O
)	)	O
phosphate	NN	O
,	,	O
USP	NNP	O
,	,	O
oral	JJ	O
solution	NN	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	DOS
mL	NNS	UNIT
to	TO	O
60	CD	DOS
mL	NN	UNIT
(	(	O
5	CD	DOS
to	TO	O
60	CD	DOS
mg	NN	UNIT
prednisolone	NN	O
base	NN	O
)	)	O
per	IN	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
tolerate	VBP	WHO
the	DT	WHO
full	JJ	WHO
intravenous	JJ	WHO
dose	NN	WHO
(	(	O
15	CD	DOS
mg	NN	UNIT
)	)	O
,	,	O
initiate	JJ	O
Lopressor	NNP	O
tablets	NNS	O
,	,	O
50	CD	DOS
mg	NN	UNIT
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
,	,	O
15	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
last	JJ	O
intravenous	JJ	O
dose	NN	O
and	CC	O
continue	VB	O
for	IN	O
48	CD	O
hours	NNS	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Clindamycin	NNP	O
Phosphate	NNP	O
Topical	NNP	O
Solution	NNP	O
twice	RB	FREQ
daily	RB	FREQ
to	TO	O
affected	JJ	O
area	NN	O
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
usual	JJ	O
dosage	NN	O
for	IN	O
persons	NNS	WHO
13	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
over	NN	WHO
is	VBZ	O
1	CD	DOS
ml	NN	UNIT
Buprenex	NNP	O
(	(	O
buprenorphine	NN	O
)	)	O
(	(	O
0.3	CD	DOS
mg	RB	UNIT
buprenorphine	NN	O
)	)	O
given	VBN	O
by	IN	O
deep	JJ	O
intramuscular	NN	O
or	CC	O
slow	VB	O
(	(	O
over	IN	O
at	IN	O
least	JJS	O
2	CD	O
minutes	NNS	O
)	)	O
intravenous	JJ	O
injection	NN	O
at	IN	O
up	IN	O
to	TO	O
6	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
,	,	O
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
DELTASONE	NNP	O
Tablets	NNP	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	DOS
mg	NNS	UNIT
to	TO	O
60	CD	DOS
mg	NN	UNIT
of	IN	O
prednisone	NN	O
per	IN	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Apply	NNP	O
Tolak	NNP	O
Cream	NNP	O
once	RB	FREQ
daily	RB	FREQ
in	IN	O
an	DT	O
amount	NN	O
sufficient	NN	O
to	TO	O
cover	VB	O
the	DT	O
lesions	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
ears	NNS	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
scalp	VBN	O
with	IN	O
a	DT	O
thin	JJ	O
film	NN	O
,	,	O
using	VBG	O
the	DT	O
fingertips	NNS	O
to	TO	O
gently	RB	O
massage	VB	O
the	DT	O
medication	NN	O
uniformly	RB	O
into	IN	O
the	DT	O
skin	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SOLODYN	NNP	O
is	VBZ	O
approximately	RB	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
once	RB	FREQ
daily	RB	FREQ
for	IN	O
12	CD	DUR
weeks	NNS	DUR
.	.	O

A	DT	O
dosage	NN	O
of	IN	O
0.024	CD	DOS
to	TO	O
0.034	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
6	CD	FREQ
to	TO	O
7	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
week	NN	FREQ
,	,	O
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
dosage	NN	O
range	NN	O
is	VBZ	O
0.2	CD	DOS
mg	NN	UNIT
to	TO	O
0.8	CD	DOS
mg	NNS	UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ELMIRON®	NNP	O
is	VBZ	O
300	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
taken	VBN	O
as	IN	O
one	CD	DOS
100	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
orally	RB	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ZYFLO	NNP	O
CR	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
asthma	NN	WHO
is	VBZ	O
two	CD	DOS
600	CD	DOS
mg	NN	UNIT
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
within	IN	O
one	CD	O
hour	NN	O
after	IN	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
,	,	O
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
2400	CD	DOS
mg.	JJ	UNIT
Tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
chewed	VBN	O
,	,	O
cut	VBD	O
or	CC	O
crushed	VBN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
four	CD	DOS
tablets	NNS	UNIT
(	(	O
one	CD	DOS
in	IN	O
the	DT	O
morning	NN	O
,	,	O
one	CD	DOS
in	IN	O
the	DT	O
mid	NN	O
-	:	O
afternoon	NN	O
and	CC	O
two	CD	DOS
at	IN	O
bedtime	NN	O
)	)	O
daily	RB	FREQ
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	DOS
to	TO	O
1.6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
3	CD	DOS
or	CC	O
4	CD	DOS
divided	VBN	UNIT
doses	NNS	UNIT
(	(	O
3.2	CD	DOS
to	TO	O
48	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²bsa	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
/	RB	O
2	CD	DOS
/	JJ	O
18	CD	DOS
tablet	NN	UNIT
)	)	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
adjusted	VBN	O
as	IN	O
necessary	JJ	O
to	TO	O
the	DT	O
size	NN	O
and	CC	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
dose	NN	O
for	IN	O
most	JJS	O
patients	NNS	O
is	VBZ	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
AMRIX	$	O
15	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
MAXZIDE	NNP	O
-	:	O
25	CD	DOS
MG	NNP	UNIT
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
daily	RB	FREQ
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
,	,	O
with	IN	O
appropriate	JJ	O
monitoring	NN	O
of	IN	O
serum	JJ	O
potassium	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
adult	NN	WHO
dose	NN	O
for	IN	O
all	DT	O
QUESTRAN	NNP	O
powdered	VBN	O
products	NNS	O
(	(	O
QUESTRAN	NNP	O
Powder	NNP	O
and	CC	O
QUESTRAN	NNP	O
Light	NNP	O
)	)	O
is	VBZ	O
one	CD	DOS
packet	NN	UNIT
or	CC	O
one	CD	DOS
level	NN	UNIT
scoopful	JJ	UNIT
once	RB	FREQ
or	CC	O
twice	VB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SAVAYSA	NNP	O
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	JJ	O
daily	JJ	FREQ
dosage	NN	O
is	VBZ	O
180	CD	DOS
mg	NN	UNIT
to	TO	O
240	CD	DOS
mg	NNS	UNIT
Inderal	JJ	O
per	IN	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
ZOSYN	NNP	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
3.375	CD	DOS
g	NN	UNIT
every	DT	FREQ
six	CD	FREQ
hours	NNS	FREQ
totaling	VBG	O
13.5	CD	DOS
g	NN	UNIT
(	(	O
12	CD	DOS
g	NN	UNIT
piperacillin	NN	O
/	VBD	O
1.5	CD	DOS
g	NNS	UNIT
tazobactam	NN	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablespoonful	NN	UNIT
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
weekly	JJ	O
intravenous	JJ	O
administration	NN	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
of	IN	O
body	NN	O
surface	JJ	O
area	NN	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
two	CD	O
courses	NNS	O
(	(	O
weeks	NNS	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
prophylactic	JJ	O
dose	NN	O
of	IN	O
RYANODEX	NNP	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	O
minute	NN	O
,	,	O
starting	VBG	O
approximately	RB	O
75	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
surgery	NN	O
.	.	O

Active	JJ	O
Duodenal	NNP	O
Ulcer	NNP	O
—	VBZ	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Nascobal	NNP	O
(	(	O
cyanocobalamin	NN	O
)	)	O
Nasal	NNP	O
Spray	NNP	O
is	VBZ	O
one	CD	DOS
spray	NN	UNIT
(	(	O
500	CD	DOS
mcg	NN	UNIT
)	)	O
administered	VBD	O
in	IN	O
ONE	CD	O
nostril	NN	O
once	RB	FREQ
weekly	JJ	FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
of	IN	O
Norpace	NNP	O
(	(	O
disopyramide	JJ	O
phosphate	NN	O
)	)	O
or	CC	O
Norpace	NNP	O
(	(	O
disopyramide	JJ	O
phosphate	NN	O
)	)	O
CR	NNP	O
is	VBZ	O
400	CD	DOS
to	TO	O
800	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

Usual	JJ	O
Dosage	NNP	O
in	IN	O
Adults	NNP	WHO
:	:	O
To	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
constipation	NN	O
,	,	O
LOTRONEX	NNP	O
(	(	O
alosetron	VB	O
hydrochloride	NN	O
)	)	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

10	CD	DOS
mL	NN	UNIT
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
doses	NNS	UNIT
(	(	O
40	CD	DOS
mL	NN	UNIT
)	)	O
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
Parlodel	NNP	O
SnapTabs®	NNP	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
½	JJ	DOS
to	TO	O
one	CD	DOS
2½	CD	DOS
mg	NN	UNIT
scored	VBD	UNIT
tablet	JJ	UNIT
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
NARDIL	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
(	(	O
15	CD	DOS
mg	NN	UNIT
)	)	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
EPIDUO	NNP	O
gel	NN	O
to	TO	O
affected	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
face	NN	O
and	CC	O
/	NN	O
or	CC	O
trunk	NN	O
once	RB	FREQ
daily	RB	FREQ
after	IN	O
washing	VBG	O
.	.	O

Adults	NNS	WHO
:	:	O
15	CD	DOS
to	TO	O
60	CD	DOS
mg	NN	UNIT
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
(	(	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
,	,	O
30	CD	DOS
mg	NN	UNIT
)	)	O
.	.	O

To	TO	O
receive	VB	O
the	DT	O
full	JJ	O
dose	NN	O
of	IN	O
medication	NN	O
,	,	O
SPIRIVA	NNP	O
RESPIMAT	NNP	O
must	MD	O
be	VB	O
administered	VBN	O
as	IN	O
two	CD	DOS
inhalations	NNS	UNIT
once	RB	FREQ
-	:	O
daily	NN	FREQ
.	.	O

Instill	NNP	O
one	CD	DOS
to	TO	O
two	CD	DOS
drops	NNS	UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
two	CD	FREQ
to	TO	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BEXTRA	NNP	O
Tablets	NNP	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
arthritis	NN	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablespoonful	NN	UNIT
(	(	O
15	CD	DOS
mL	NN	UNIT
)	)	O
every	DT	FREQ
four	CD	FREQ
to	TO	FREQ
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Oleptro	NNP	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
adults	NNS	WHO
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Abciximab	NNP	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
a	DT	O
0.25	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
intravenous	JJ	DOS
bolus	NN	UNIT
administered	VBD	O
10	CD	O
-	:	O
60	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
PCI	NNP	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
0.125	CD	DOS
μg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
(	(	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
10	CD	O
μg	JJ	O
/	NNP	O
min	NN	O
)	)	O
for	IN	O
12	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
is	VBZ	O
0.25	CD	DOS
mg	NN	UNIT
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Astelin	NNP	O
Nasal	NNP	O
Spray	NNP	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
adolescent	JJ	WHO
patients	NNS	WHO
12	CD	O
years	NNS	O
and	CC	O
older	JJR	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
sprays	NNS	UNIT
per	IN	O
nostril	JJ	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
1000	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Daily	JJ	FREQ
doses	NNS	O
of	IN	O
ZOHYDRO	NNP	O
ER	NNP	O
,	,	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
greater	JJR	O
than	IN	O
40	CD	DOS
mg	NN	UNIT
,	,	O
or	CC	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
greater	JJR	O
than	IN	O
80	CD	DOS
mg	NN	UNIT
,	,	O
are	VBP	O
only	RB	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	WHO
in	IN	WHO
whom	WP	WHO
tolerance	NN	WHO
to	TO	WHO
an	DT	WHO
opioid	NN	WHO
of	IN	WHO
comparable	JJ	WHO
potency	NN	WHO
has	VBZ	WHO
been	VBN	WHO
established	VBN	WHO
.	.	O

The	DT	O
usual	JJ	O
IV	NNP	O
dose	NN	O
is	VBZ	O
16	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
Diaβeta	NNP	O
as	IN	O
initial	JJ	O
therapy	NN	O
is	VBZ	O
2.5	CD	DOS
to	TO	O
5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
,	,	O
administered	VBN	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TORISEL	NNP	O
for	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
infused	VBN	O
over	IN	O
a	DT	O
30	CD	O
–	NN	O
60	CD	O
minute	NN	O
period	NN	O
once	IN	FREQ
a	DT	FREQ
week	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Orenitram	NNP	O
is	VBZ	O
0.25	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
BID	NNP	O
)	)	O
with	IN	O
food	NN	O
,	,	O
taken	VBN	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
or	CC	O
0.125	CD	DOS
mg	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
TID	NNP	O
)	)	O
with	IN	O
food	NN	O
,	,	O
taken	VBN	O
approximately	RB	O
8	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
recommended	JJ	O
regimen	NN	O
is	VBZ	O
a	DT	O
5	CD	DOS
mg	NN	UNIT
infusion	NN	O
once	RB	FREQ
a	DT	FREQ
year	NN	FREQ
given	VBN	O
intravenously	RB	O
over	IN	O
no	DT	O
less	JJR	O
than	IN	O
15	CD	O
minutes	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VIVITROL	NNP	O
is	VBZ	O
380	CD	DOS
mg	NN	UNIT
delivered	VBD	O
intramuscularly	RB	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
or	CC	O
once	RB	FREQ
a	DT	FREQ
month	NN	FREQ
.	.	O

PULMICORT	NNP	O
FLEXHALER	NNP	O
(	(	O
budesonide	JJ	O
inhalation	NN	O
powder	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
twice	RB	FREQ
daily	RB	FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

A	DT	O
thin	JJ	O
film	NN	O
is	VBZ	O
applied	VBN	O
2	CD	FREQ
to	TO	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dosage	NN	O
for	IN	O
VIIBRYD	NNP	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
to	TO	O
40	CD	DOS
mg	NNS	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
food	NN	O
.	.	O

Initial	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
100	CD	DOS
to	TO	O
200	CD	DOS
mL	NNS	UNIT
and	CC	O
for	IN	O
children	NNS	WHO
2.5	CD	DOS
to	TO	O
5	CD	DOS
mL	NNS	UNIT
per	IN	O
kilogram	NN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
for	IN	O
PROVENGE	NNP	O
is	VBZ	O
3	CD	DOS
complete	JJ	UNIT
doses	NNS	UNIT
,	,	O
given	VBN	O
at	IN	O
approximately	RB	O
2	CD	O
-	:	O
week	NN	O
intervals	NNS	O
.	.	O

The	DT	O
dosage	NN	O
range	NN	O
of	IN	O
LIPTRUZET	NNP	O
is	VBZ	O
10	CD	DOS
/	JJ	O
10	CD	O
/	JJ	O
18	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
to	TO	O
10	CD	DOS
/	NNS	O
80	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Apply	VB	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
the	DT	O
84	CD	O
-	:	O
gram	NN	O
package	NN	O
of	IN	O
SERPACWA	NNP	O
evenly	RB	O
to	TO	O
the	DT	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
as	IN	O
outlined	VBN	O
in	IN	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
for	IN	O
Military	NNP	O
Personnel	NNP	O
below	IN	O
)	)	O
prior	RB	O
to	TO	O
donning	VBG	O
MOPP	NNP	O
gear	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Sotret	NNP	O
(	(	O
isotret	JJ	O
(	(	O
isotret	JJ	O
(	(	O
isotretinoin	JJ	O
capsules	NNS	O
)	)	O
inoin	VBP	O
capsules	NNS	O
)	)	O
inoin	VBP	O
capsules	NNS	O
)	)	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	DUR
to	TO	O
20	CD	DUR
weeks	NNS	DUR
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
two	CD	DOS
capsules	NNS	UNIT
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

FLOMAX	NNP	O
capsules	VBZ	O
0.4	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
is	VBZ	O
recommended	VBN	O
as	IN	O
the	DT	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
BPH	NNP	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
0.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
minoxidil	NN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
romidepsin	NN	O
is	VBZ	O
14	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
4	CD	O
-	:	O
hour	NN	O
period	NN	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
of	IN	O
a	DT	O
28	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
OLYSIO	NNP	O
is	VBZ	O
one	CD	DOS
150	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Zenatane	NNP	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	DUR
to	TO	O
20	CD	DUR
weeks	NNS	DUR
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HIV	NNP	O
-	:	O
1	CD	DOS
or	CC	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
:	:	O
The	DT	O
dose	NN	O
is	VBZ	O
one	CD	DOS
300	CD	DOS
mg	NN	UNIT
VIREAD	NNP	UNIT
tablet	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
taken	VBN	O
orally	RB	O
,	,	O
without	IN	O
regard	NN	O
to	TO	O
food	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
patient	NN	O
be	VB	O
started	VBN	O
on	IN	O
200	CD	DOS
mg	NNS	UNIT
,	,	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
RELISTOR	NNP	O
is	VBZ	O
12	CD	DOS
mg	NN	UNIT
subcutaneously	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
5	CD	DOS
to	TO	O
40	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
8	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

Hodgkin	NNP	O
's	POS	O
disease	NN	O
-	:	O
0.25	CD	DOS
to	TO	O
0.5	CD	DOS
units	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
10	CD	DOS
to	TO	O
20	CD	DOS
units	NNS	UNIT
/	NNP	O
m²	NN	O
)	)	O
given	VBN	O
intravenously	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
or	CC	O
subcutaneously	RB	O
weekly	JJ	FREQ
or	CC	O
twice	JJ	FREQ
weekly	RB	FREQ
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
1.2	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
maximum	JJ	O
dosing	NN	O
frequency	NN	O
is	VBZ	O
one	CD	DOS
STAXYN	NNP	UNIT
tablet	NN	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
or	CC	O
60	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
for	IN	O
systemic	JJ	O
and	CC	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
3.1	CD	DOS
grams	NNS	UNIT
of	IN	O
TIMENTIN	NNP	O
(	(	O
3	CD	DOS
grams	NNS	UNIT
ticarcillin	NN	O
and	CC	O
100	CD	DOS
mg	NN	UNIT
clavulanic	JJ	O
acid	NN	O
)	)	O
given	VBN	O
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
PEDIAPRED	NNP	O
(	(	O
prednisolone	JJ	O
sodium	NN	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	DOS
mL	NNS	UNIT
to	TO	O
60	CD	DOS
mL	NN	UNIT
(	(	O
5	CD	DOS
to	TO	O
60	CD	DOS
mg	NN	UNIT
prednisolone	NN	O
base	NN	O
)	)	O
per	IN	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

SIMCOR	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
at	IN	O
bedtime	NN	O
,	,	O
with	IN	O
a	DT	O
low	JJ	O
fat	JJ	O
snack	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Fortical	NNP	O
nasal	NN	O
spray	NN	O
is	VBZ	O
1	CD	DOS
spray	NN	UNIT
(	(	O
200	CD	DOS
International	NNP	UNIT
Units	NNP	UNIT
)	)	O
per	IN	FREQ
day	NN	FREQ
intranasally	RB	O
,	,	O
alternating	VBG	O
nostrils	JJ	O
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	DOS
to	TO	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
daily	JJ	FREQ
intravenously	RB	O
for	IN	O
8	CD	DUR
to	TO	O
14	CD	DUR
days	NNS	DUR
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	WHO
for	IN	O
maintenance	NN	O
of	IN	O
remission	NN	O
is	VBZ	O
1	CD	DOS
g	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
range	NN	O
for	IN	O
FETZIMA	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
to	TO	O
120	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
2	CD	DOS
to	TO	O
4	CD	DOS
g	NNS	UNIT
intravaginally	RB	O
per	IN	FREQ
day	NN	FREQ
,	,	O
adjusted	VBN	O
to	TO	O
the	DT	O
lowest	JJS	O
amount	NN	O
that	WDT	O
controls	VBZ	O
symptoms	NNS	O
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
COZAAR	NNP	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Apply	RB	O
1	CD	DOS
–	JJ	O
4	CD	DOS
pumps	NNS	UNIT
up	RB	O
to	TO	O
four	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
complicated	VBN	O
skin	NN	O
and	CC	O
skin	NN	O
structure	NN	O
infections	NNS	O
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
q12h	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
FARESTON	NNP	O
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
,	,	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
orally	RB	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
eczematous	JJ	O
external	JJ	O
otitis	NN	O
,	,	O
using	VBG	O
the	DT	O
supplied	JJ	O
ear	JJ	O
-	:	O
dropper	NN	O
,	,	O
apply	VB	O
5	CD	DOS
drops	NNS	UNIT
of	IN	O
DermOtic®	NNP	O
Oil	NNP	O
(	(	O
fluocinolone	NN	O
acetonide	RB	O
oil	NN	O
ear	JJ	O
drops	NN	O
)	)	O
into	IN	O
the	DT	O
affected	JJ	O
ear	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
for	IN	O
tablets	NNS	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
to	TO	O
60	CD	DOS
mg	NNS	UNIT
repeated	VBD	O
up	RB	O
to	TO	O
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

This	DT	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
5	CD	FREQ
to	TO	O
6	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
5	CD	DOS
to	TO	O
6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
daily	JJ	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ETHYOL	NNP	O
(	(	O
amifostine	NN	O
)	)	O
is	VBZ	O
910	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
administered	VBD	O
once	RB	FREQ
daily	JJ	FREQ
as	IN	O
a	DT	O
15	CD	DOS
-	:	O
minute	NN	O
i.v	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosages	NNS	O
of	IN	O
ELLENCE	NNP	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ELLENCE	NNP	O
is	VBZ	O
100	CD	DOS
to	TO	O
120	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	NN	O
.	.	O

For	IN	O
management	NN	O
of	IN	O
bronchial	JJ	O
asthma	NN	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
(	(	O
two	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
over	IN	O
)	)	O
,	,	O
the	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
the	DT	O
contents	NNS	O
of	IN	O
one	CD	DOS
ampule	NN	UNIT
administered	VBN	O
by	IN	O
nebulization	NN	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
at	IN	O
regular	JJ	O
intervals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Corlanor	NNP	O
is	VBZ	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
with	IN	O
meals	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
CALCIJEX®	NNP	O
is	VBZ	O
0.5	CD	DOS
mcg	NN	UNIT
(	(	O
0.01	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
administered	VBD	O
three	CD	FREQ
times	NNS	FREQ
weekly	RB	FREQ
,	,	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

A	DT	O
dose	NN	O
of	IN	O
1	CD	DOS
capsule	NN	UNIT
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
is	VBZ	O
suggested	VBN	O
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	DOS
to	TO	O
1.6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
three	CD	DOS
or	CC	O
four	CD	DOS
divided	VBN	UNIT
doses	NNS	UNIT
(	(	O
3.2	CD	DOS
to	TO	O
48	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²bsa	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
NATRECOR®	NNP	O
is	VBZ	O
an	DT	O
IV	NNP	O
bolus	NN	O
of	IN	O
2	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
0.01	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	JJ	O
min	NN	O
.	.	O

The	DT	O
usual	JJ	O
parenteral	NN	O
dose	NN	O
is	VBZ	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
given	VBN	O
subcutaneously	RB	O
or	CC	O
intramuscularly	RB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
and	CC	O
target	NN	O
dose	NN	O
for	IN	O
ABILIFY	NNP	O
is	VBZ	O
10	CD	DOS
or	CC	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
administered	VBD	O
on	IN	O
a	DT	O
once	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
schedule	NN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
HARVONI	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ODEFSEY	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
a	DT	O
meal	NN	O
in	IN	O
the	DT	O
following	JJ	O
patient	JJ	O
population	NN	O
:	:	O
adults	NNS	WHO
and	CC	WHO
in	IN	WHO
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
with	IN	WHO
body	NN	WHO
weight	NN	WHO
greater	JJR	WHO
than	IN	WHO
or	CC	O
equal	JJ	O
to	TO	O
35	CD	O
kg	NNS	O
and	CC	O
a	DT	O
creatinine	JJ	O
clearance	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
30	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REBIF	NNP	O
is	VBZ	O
either	RB	O
22	CD	DOS
mcg	NN	UNIT
or	CC	O
44	CD	DOS
mcg	NNS	UNIT
injected	VBD	O
subcutaneously	RB	O
three	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
1	CD	DOS
or	CC	O
2	CD	DOS
mg	NN	UNIT
2	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
3	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
four	CD	O
to	TO	O
twelve	VB	O
hours	NNS	O
apart	RB	O
for	IN	O
7	CD	DUR
days	NNS	DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ZYTIGA	NNP	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
250	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
administered	VBD	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
combination	NN	O
with	IN	O
prednisone	NN	O
5	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
twice	JJ	FREQ
daily	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
OptiPranolol	NNP	O
(	(	O
metipranolol	JJ	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
Ophthalmic	NNP	O
Solution	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Apply	VB	O
the	DT	O
0.1	CD	O
%	NN	O
HALOG	NNP	O
(	(	O
Halcinonide	NNP	O
Cream	NNP	O
,	,	O
USP	NNP	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
two	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initiating	NN	O
dose	NN	O
of	IN	O
TRULICITY	NNP	O
is	VBZ	O
0.75	CD	DOS
mg	NN	UNIT
once	RB	FREQ
weekly	JJ	FREQ
.	.	O

Adults	NNS	O
:	:	O
1	CD	DOS
or	CC	O
2	CD	DOS
capsules	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Take	VB	O
10	CD	DOS
mg	NNS	UNIT
to	TO	O
15	CD	DOS
mg	NNS	UNIT
dose	NN	O
of	IN	O
METOZOLV	NNP	O
ODT	NNP	O
up	RB	O
to	TO	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
e.g	NN	O
.	.	O
,	,	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
before	IN	O
each	DT	O
meal	NN	O
and	CC	O
at	IN	O
bedtime	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
atorvastatin	NN	O
is	VBZ	O
10	CD	DOS
or	CC	O
20	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
CYSTAGON®	NNP	O
(	(	O
cysteamine	JJ	O
bitartrate	NN	O
)	)	O
maintenance	NN	O
dose	NN	O
for	IN	O
children	NNS	O
up	RB	O
to	TO	O
age	NN	O
12	CD	O
years	NNS	O
is	VBZ	O
1.3	CD	DOS
grams	NNS	UNIT
/	VBP	O
m2	JJ	O
/	NNP	FREQ
day	NN	FREQ
of	IN	O
the	DT	O
free	JJ	O
base	NN	O
,	,	O
given	VBN	O
in	IN	O
four	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

For	IN	O
most	JJS	WHO
patients	NNS	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLEXERIL	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

For	IN	O
the	DT	O
short	JJ	O
-	:	O
term	NN	O
(	(	O
generally	RB	O
less	JJR	O
than	IN	O
10	CD	O
days	NNS	O
)	)	O
management	NN	O
of	IN	O
acute	NN	O
pain	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REPREXAIN™	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	O
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
,	,	O
as	IN	O
necessary	JJ	O
.	.	O

For	IN	O
peripheral	JJ	O
intravenous	JJ	O
infusion	NN	O
,	,	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
of	IN	O
total	JJ	O
amino	NN	O
acids	NNS	O
will	MD	O
reduce	VB	O
protein	JJ	O
catabolism	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Pamidronate	NNP	O
disodium	NN	O
for	IN	O
Injection	NNP	O
USP	NNP	O
in	IN	O
severe	JJ	O
hypercalcemia	NN	O
(	(	O
corrected	VBN	O
serum	NN	O
calcium*	NN	O
>	VBD	O
13.5	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
)	)	O
is	VBZ	O
90	CD	DOS
mg	NN	UNIT
given	VBN	O
as	IN	O
a	DT	O
SINGLE	NNP	DOS
-	:	O
DOSE	NNP	UNIT
,	,	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
2	CD	O
to	TO	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
PCE	NNP	O
tablets	NNS	O
are	VBP	O
one	CD	DOS
333	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
or	CC	O
one	CD	DOS
500	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMERGE	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
or	CC	O
2.5	CD	DOS
mg	NN	UNIT
.	.	O

Generally	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Dritho	NNP	O
-	:	O
Scalp	NN	O
be	VB	O
applied	VBN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

1	CD	DOS
or	CC	O
2	CD	DOS
capsules	NNS	UNIT
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
suggested	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
between	IN	O
0.2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
hr*	NN	FREQ
,	,	O
and	CC	O
0.4	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
hr*	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
REMERONSolTab®	NNP	O
(	(	O
mirtazapine	NN	O
)	)	O
Orally	RB	O
Disintegrating	VBG	O
Tablets	NNP	O
is	VBZ	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
evening	NN	O
prior	RB	O
to	TO	O
sleep	VB	O
.	.	O

Metastatic	JJ	O
Testicular	NNP	O
Tumors	NNPS	O
-	:	O
The	DT	O
usual	JJ	O
cisplatin	NN	O
(	(	O
cisplatin	JJ	O
injection	NN	O
)	)	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
testicular	JJ	O
cancer	NN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
approved	VBN	O
chemotherapeutic	JJ	O
agents	NNS	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
IV	NNP	O
daily	RB	FREQ
for	IN	O
5	CD	DUR
days	NNS	DUR
per	IN	O
cycle	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
dose	NN	O
of	IN	O
Oforta™	NNP	O
(	(	O
fludarabine	JJ	O
phosphate	NN	O
tablets	NNS	O
)	)	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
/	NNP	O
m	NN	O
administered	VBN	O
by	IN	O
mouth	JJ	O
daily	JJ	FREQ
for	IN	O
five	CD	DUR
consecutive	JJ	DUR
days	NNS	DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
25	CD	DOS
to	TO	O
40	CD	DOS
IU	NNP	UNIT
of	IN	O
IDELVION	NNP	O
per	IN	O
kg	NN	O
body	NN	O
weight	VBD	O
every	DT	FREQ
7	CD	FREQ
days	NNS	FREQ
,	,	O
or	CC	O
50	CD	DOS
to	TO	O
75	CD	DOS
IU	NNP	UNIT
of	IN	O
IDELVION	NNP	O
per	IN	O
kg	NN	O
every	DT	FREQ
14	CD	FREQ
days	NNS	FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
two	CD	DOS
(	(	O
2	CD	DOS
)	)	O
TREZIX™	NNP	DOS
capsules	NNS	UNIT
orally	RB	O
every	DT	FREQ
four	CD	FREQ
(	(	O
4	CD	FREQ
)	)	O
hours	NNS	FREQ
,	,	O
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
maximum	JJ	O
daily	JJ	FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
12	CD	DOS
grams	NNS	UNIT
.	.	O

The	DT	O
initial	JJ	O
intramuscular	JJ	O
dosage	NN	O
of	IN	O
triamcinolone	NN	O
diacetate	NN	O
injectable	JJ	O
suspension	NN	O
may	MD	O
vary	VB	O
from	IN	O
3	CD	DOS
to	TO	O
48	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablespoonful	NN	UNIT
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Usual	JJ	O
dose	NN	O
is	VBZ	O
5	CD	DOS
to	TO	O
60	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

For	IN	O
intravenous	JJ	O
use	NN	O
,	,	O
Novolin	NNP	O
R	NNP	O
should	MD	O
be	VB	O
used	VBN	O
at	IN	O
concentrations	NNS	O
from	IN	O
0.05	CD	DOS
units	NNS	UNIT
/	RB	O
mL	VBP	O
to	TO	O
1	CD	DOS
unit	NN	UNIT
/	JJ	O
mL	NN	O
in	IN	O
infusion	NN	O
systems	NNS	O
using	VBG	O
polypropylene	JJ	O
infusion	NN	O
bags	NNS	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
50	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INCIVEK	NNP	O
tablets	NNS	O
is	VBZ	O
1125	CD	DOS
mg	NN	UNIT
(	(	O
three	CD	DOS
375	CD	DOS
-	:	O
mg	NN	UNIT
tablets	NNS	UNIT
)	)	O
taken	VBN	O
orally	RB	O
twice	JJ	FREQ
daily	RB	FREQ
(	(	O
10	CD	O
-	:	O
14	CD	O
hours	NNS	O
apart	RB	O
)	)	O
with	IN	O
food	NN	O
(	(	O
not	RB	O
low	JJ	O
fat	NN	O
)	)	O
.	.	O

Treatment	NN	O
of	IN	O
Testicular	JJ	O
Tumors	NNS	O
:	:	O
In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
testicular	JJ	WHO
tumors	NNS	WHO
the	DT	O
recommended	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
Mithracin	NNP	O
(	(	O
plicamycin	NN	O
)	)	O
is	VBZ	O
25	CD	DOS
to	TO	O
30	CD	DOS
mcg	NN	UNIT
(	(	O
0.025	CD	DOS
-	:	O
0.03	CD	DOS
mg	NN	UNIT
)	)	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
0.0625	CD	DOS
mg	NN	UNIT
(	(	O
0.25	CD	DOS
mL	NN	UNIT
)	)	O
subcutaneously	RB	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
,	,	O
with	IN	O
dose	JJ	O
increases	NNS	O
over	IN	O
a	DT	O
six	CD	O
-	:	O
week	NN	O
period	NN	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
0.25	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
mL	NN	UNIT
)	)	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Feraheme	NNP	O
is	VBZ	O
an	DT	O
initial	JJ	O
510	CD	DOS
mg	NN	UNIT
dose	NN	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
510	CD	DOS
mg	NN	UNIT
dose	VBD	O
3	CD	O
to	TO	O
8	CD	O
days	NNS	O
later	RB	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	NN	FREQ
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
CORTEF	NNP	O
Tablets	NNP	O
may	MD	O
vary	VB	O
from	IN	O
20	CD	DOS
mg	NNS	UNIT
to	TO	O
240	CD	DOS
mg	NN	UNIT
of	IN	O
hydrocortisone	NN	O
per	IN	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
to	TO	O
affected	VBN	O
areas	NNS	O
with	IN	O
light	JJ	O
massaging	VBG	O
,	,	O
1	CD	FREQ
to	TO	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

The	DT	O
dosage	NN	O
delivered	VBN	O
is	VBZ	O
0.5	CD	DOS
-	:	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
edrophonium	NN	O
chloride	NN	O
and	CC	O
0.007	CD	DOS
-	:	O
0.014	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
atropine	JJ	O
sulfate	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
doxorubicin	NN	O
HCl	NNP	O
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
/	NNP	O
m	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
treatment	NN	O
cycle	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
cycles	NNS	O
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Asacol	NNP	O
is	VBZ	O
two	CD	DOS
400	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
to	TO	O
be	VB	O
taken	VBN	O
three	CD	FREQ
times	NNS	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
(	(	O
total	JJ	O
daily	RB	FREQ
dose	NN	O
of	IN	O
2.4	CD	DOS
grams	NNS	UNIT
)	)	O
,	,	O
for	IN	O
a	DT	O
duration	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
[	JJ	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Toenail	JJ	O
onychomycosis	NN	O
:	:	O
One	CD	DOS
250	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
12	CD	DUR
weeks	NNS	DUR
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
moderately	RB	WHO
severe	JJ	WHO
chronic	NN	WHO
pain	NN	WHO
not	RB	O
requiring	VBG	O
rapid	JJ	O
onset	NN	O
of	IN	O
analgesic	JJ	O
effect	NN	O
,	,	O
the	DT	O
tolerability	NN	O
of	IN	O
ULTRAM®	NNP	O
can	MD	O
be	VB	O
improved	VBN	O
by	IN	O
initiating	VBG	O
therapy	NN	O
with	IN	O
the	DT	O
following	JJ	O
titration	NN	O
regimen	NNS	O
:	:	O
ULTRAM®	NNP	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
25	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
half	JJ	DOS
ULTRAM®	NNP	DOS
scored	VBD	UNIT
tablet	NN	UNIT
)	)	O
qAM	NN	O
and	CC	O
titrated	VBN	O
in	IN	O
25	CD	DOS
mg	NN	UNIT
increments	NNS	O
as	IN	O
separate	JJ	O
doses	NNS	O
every	DT	FREQ
3	CD	FREQ
days	NNS	FREQ
to	TO	O
reach	VB	O
100	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
25	CD	DOS
mg	NN	UNIT
q.i.d	NN	O
.	.	O
)	)	O
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
.	.	O

A	DT	O
small	JJ	O
amount	NN	O
of	IN	O
CENTANY®	NNP	O
ointment	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

PrandiMet	NN	O
can	MD	O
be	VB	O
administered	VBN	O
2	CD	FREQ
to	TO	O
3	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
up	RP	O
to	TO	O
a	DT	O
maximum	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
repaglinide	RB	O
/	IN	O
2500	CD	DOS
mg	NN	UNIT
metformin	NN	O
HCl	NNP	O
.	.	O

VICODIN®	NNP	O
(	(	O
Hydrocodone	NNP	O
Bitartrate	NNP	O
and	CC	O
Acetaminophen	NNP	O
Tablets	NNP	O
,	,	O
USP	NNP	O
5	CD	DOS
mg	NN	UNIT
/	VBD	O
300	CD	DOS
mg	NN	UNIT
)	)	O
:	:	O
The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
for	IN	O
14	CD	DUR
days	NNS	DUR
followed	VBN	O
by	IN	O
tapering	VBG	O
as	IN	O
clinically	RB	O
indicated	VBN	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
cortisone	NN	O
acetate	NN	O
may	MD	O
vary	VB	O
from	IN	O
25	CD	DOS
to	TO	O
300	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SANCTURA	NNP	O
XR®	NNP	O
is	VBZ	O
one	CD	DOS
60	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	DOS
to	TO	O
1.6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
three	CD	DOS
or	CC	O
four	CD	DOS
divided	VBN	UNIT
doses	NNS	UNIT
(	(	O
3.2	CD	DOS
to	TO	O
48	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²bsa	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
.	.	O

RETIN	NNP	O
-	:	O
A	DT	O
Gel	NNP	O
,	,	O
Cream	NNP	O
or	CC	O
Liquid	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
before	IN	O
retiring	VBG	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
enough	JJ	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
lightly	RB	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
DORIBAX®	NNP	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
administered	VBN	O
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
one	CD	O
hour	NN	O
in	IN	O
patients	NNS	WHO
≥	JJ	WHO
18	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
30	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
.	.	O

Breast	NNP	O
cancer	NN	O
:	:	O
160	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
40	CD	DOS
mg	NN	UNIT
q.i.d	NN	O
.	.	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
160	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	DOS
80	CD	DOS
mg	NNS	UNIT
injections	NNS	UNIT
)	)	O
at	IN	O
Week	NNP	O
0	CD	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	DOS
mg	NNS	UNIT
at	IN	O
Weeks	NNP	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
12	CD	O
,	,	O
then	RB	O
80	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PERIKABIVEN®	NNP	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
27	CD	DOS
to	TO	O
40	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
of	IN	O
RIDAURA	NNP	O
(	(	O
auranofin	NN	O
)	)	O
is	VBZ	O
6	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
,	,	O
given	VBN	O
either	CC	O
as	IN	O
3	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
or	CC	O
6	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

TO	NNP	O
TREAT	NNP	O
THE	NNP	O
EYE	NNP	O
:	:	O
Instill	NNP	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
every	DT	FREQ
3	CD	FREQ
or	CC	O
4	CD	FREQ
hours	NNS	FREQ
,	,	O
or	CC	O
more	RBR	O
frequently	RB	O
as	IN	O
required	VBN	O
.	.	O

Take	VB	O
one	CD	DOS
tablet	NN	UNIT
by	IN	O
mouth	NN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
every	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
EPIVIR	NNP	O
in	IN	O
HIV	NNP	O
-	:	O
1	CD	DOS
-	:	O
infected	VBN	O
adults	NNS	WHO
is	VBZ	O
300	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
,	,	O
administered	VBN	O
as	IN	O
either	DT	O
150	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
twice	JJ	FREQ
daily	RB	FREQ
or	CC	O
300	CD	DOS
mg	NNS	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

CLINDETS®	NNP	O
(	(	O
clindamycin	JJ	O
phosphate	NN	O
pledget	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
areas	NNS	O
affected	VBN	O
by	IN	O
acne	JJ	O
twice	JJ	FREQ
daily	RB	FREQ
,	,	O
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
at	IN	O
night	NN	O
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
episodes	NNS	O
of	IN	O
bronchospasm	NN	O
or	CC	O
prevention	NN	O
of	IN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
bronchospasm	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
4	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
older	JJR	WHO
is	VBZ	O
2	CD	DOS
inhalations	NNS	UNIT
repeated	VBN	O
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
dose	NN	O
of	IN	O
GAMUNEX	NNP	O
-	:	O
C	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
PI	NNP	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
to	TO	O
600	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
(	(	O
3	CD	DOS
mL	NN	UNIT
/	NN	O
kg	NN	O
to	TO	O
6	CD	DOS
mL	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
administered	VBD	O
every	DT	FREQ
3	CD	FREQ
to	TO	O
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IBRANCE	NNP	O
is	VBZ	O
a	DT	O
125	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
21	CD	DUR
consecutive	JJ	DUR
days	NNS	DUR
followed	VBN	O
by	IN	O
7	CD	DUR
days	NNS	DUR
off	RB	O
treatment	NN	O
to	TO	O
comprise	VB	O
a	DT	O
complete	JJ	O
cycle	NN	O
of	IN	O
28	CD	O
days	NNS	O
.	.	O

One	CD	DOS
RAGWITEK	NNP	UNIT
tablet	NN	UNIT
daily	RB	FREQ
.	.	O

Chlorthalidone	NN	O
is	VBZ	O
usually	RB	O
given	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	DOS
mg	JJ	UNIT
daily	RB	O
;	:	O
the	DT	O
usual	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
atenolol	NN	O
is	VBZ	O
50	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
PLATINOL	NNP	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
testicular	JJ	O
cancer	NN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
approved	VBN	O
chemotherapeutic	JJ	O
agents	NNS	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
IV	NNP	O
daily	RB	FREQ
for	IN	O
5	CD	DUR
days	NNS	DUR
per	IN	O
cycle	NN	O
.	.	O

The	DT	O
SIMPONI	NNP	O
ARIA	NNP	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
at	IN	O
weeks	NNS	O
0	CD	O
and	CC	O
4	CD	O
,	,	O
then	RB	O
every	DT	FREQ
8	CD	FREQ
weeks	NNS	FREQ
thereafter	RB	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBN	O
adult	NN	WHO
dose	NN	O
of	IN	O
IMITREX	NNP	O
Injection	NNP	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
or	CC	O
cluster	NN	O
headache	NN	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
injected	VBD	O
subcutaneously	RB	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
0.25	CD	O
%	NN	O
TIMOPTIC	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
applicator	NN	UNIT
full	JJ	O
of	IN	O
METROGEL	NNP	O
-	:	O
VAGINAL	NNP	O
(	(	O
approximately	RB	O
5	CD	DOS
grams	NNS	UNIT
containing	VBG	O
approximately	RB	O
37.5	CD	DOS
mg	NNS	UNIT
of	IN	O
metronidazole	NN	O
)	)	O
intravaginally	RB	O
once	RB	FREQ
or	CC	O
twice	VB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
5	CD	DUR
days	NNS	DUR
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Focalin	NNP	O
XR	NNP	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
currently	RB	WHO
taking	VBG	WHO
dexmethylphenidate	NN	WHO
or	CC	WHO
racemic	JJ	WHO
methylphenidate	NN	WHO
,	,	O
or	CC	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
on	IN	WHO
stimulants	NNS	WHO
other	JJ	WHO
than	IN	WHO
methylphenidate	NN	WHO
,	,	O
is	VBZ	O
5	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
and	CC	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
adult	NN	WHO
patients	NNS	WHO
.	.	O

The	DT	O
starting	NN	O
dose	NN	O
is	VBZ	O
12.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
65	CD	DOS
mg	NN	UNIT
propoxyphene	NN	UNIT
hydrochloride	NN	UNIT
capsule	NN	UNIT
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SARAFEM	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
PMDD	NNP	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
continuously	RB	O
(	(	O
every	DT	FREQ
day	NN	FREQ
of	IN	O
the	DT	O
menstrual	JJ	O
cycle	NN	O
)	)	O
or	CC	O
intermittently	RB	O
(	(	O
defined	VBN	O
as	IN	O
starting	VBG	O
a	DT	O
daily	JJ	FREQ
dose	JJ	FREQ
14	CD	O
days	NNS	O
prior	RB	O
to	TO	O
the	DT	O
anticipated	JJ	O
onset	NN	O
of	IN	O
menstruation	NN	O
through	IN	O
the	DT	O
first	JJ	O
full	JJ	O
day	NN	O
of	IN	O
menses	NNS	O
and	CC	O
repeating	VBG	O
with	IN	O
each	DT	O
new	JJ	O
cycle	NN	O
)	)	O
.	.	O

Usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	DOS
capsules	NNS	UNIT
daily	RB	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

The	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
LOVAZA	NNP	O
is	VBZ	O
4	CD	DOS
grams	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
intravenous	JJ	O
dose	NN	O
is	VBZ	O
1.5	CD	DOS
to	TO	O
5	CD	DOS
mL	NNS	UNIT
per	IN	O
varix	NN	O
.	.	O

15	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
orally	RB	O
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
for	IN	O
6	CD	O
doses	NNS	O
.	.	O

DIFFERIN®	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
affected	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
nighttime	NN	O
.	.	O

TOBI	NNP	O
Podhaler	NNP	O
is	VBZ	O
administered	VBN	O
twice	RB	FREQ
-	:	O
daily	JJ	FREQ
in	IN	O
alternating	VBG	O
periods	NNS	O
of	IN	O
28	CD	O
days	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	O
with	IN	WHO
hypertension	NN	WHO
taking	VBG	WHO
diuretics	NNS	WHO
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	O
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BAVENCIO	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
30	CD	DUR
days	NNS	DUR
,	,	O
followed	VBD	O
thereafter	RB	O
by	IN	O
150	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
AVAPRO	NNP	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ProstaScint®	NNP	O
(	(	O
c	JJ	O
apromab	RB	O
pendetide	NN	O
)	)	O
is	VBZ	O
0.5	CD	DOS
mg	NN	UNIT
radiolabeled	VBD	O
with	IN	O
5	CD	DOS
mCi	NNS	UNIT
of	IN	O
Indium	NNP	O
In	IN	O
111	CD	O
chloride	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
LIPITOR	NNP	O
is	VBZ	O
10	CD	DOS
or	CC	O
20	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TYKERB	NNP	O
is	VBZ	O
1250	CD	DOS
mg	NN	UNIT
given	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
on	IN	O
Days	NNS	O
1	CD	O
-	:	O
21	CD	O
continuously	RB	O
in	IN	O
combination	NN	O
with	IN	O
capecitabine	JJ	O
2000	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
/	NNP	FREQ
day	NN	FREQ
(	(	O
administered	VBN	O
orally	RB	O
in	IN	O
2	CD	DOS
doses	NNS	UNIT
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
on	IN	O
Days	$	O
1	CD	O
-	:	O
14	CD	O
in	IN	O
a	DT	O
repeating	VBG	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
50	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
is	VBZ	O
recommended	VBN	O
for	IN	O
most	JJS	WHO
patients	NNS	WHO
.	.	O

The	DT	O
maximum	NN	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
9	CD	DOS
breaths	NNS	UNIT
per	IN	O
treatment	NN	O
session	NN	O
,	,	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Instill	NNP	O
four	CD	DOS
drops	NNS	UNIT
into	IN	O
the	DT	O
affected	JJ	O
ear	NN	O
(	(	O
s	PRP	O
)	)	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
seven	CD	DUR
days	NNS	DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FUZEON	NNP	O
is	VBZ	O
90	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
mL	NN	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
injected	VBN	O
subcutaneously	RB	O
into	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
,	,	O
anterior	JJ	O
thigh	NN	O
or	CC	O
abdomen	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SIVEXTRO	NNP	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
six	CD	DUR
(	(	O
6	CD	DUR
)	)	O
days	NNS	DUR
either	CC	O
orally	RB	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
)	)	O
or	CC	O
as	IN	O
an	DT	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
in	IN	O
patients	NNS	WHO
18	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
older	JJR	WHO
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
for	IN	O
oral	JJ	O
administration	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
.	.	O

A	DT	O
1000	CD	O
second	NN	O
(	(	O
16	CD	O
minutes	NNS	O
40	CD	O
seconds	NNS	O
)	)	O
exposure	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
provide	VB	O
a	DT	O
10	CD	O
J	NNP	O
/	NNP	O
cm²	NN	O
light	NN	O
dose	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BELVIQ	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
SPRYCEL	NNP	O
for	IN	O
chronic	JJ	O
phase	NN	O
CML	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
ACLOVATE®	NNP	O
(	(	O
alclometasone	JJ	O
dipropionate	NN	O
)	)	O
Cream	NN	O
or	CC	O
Ointment	NN	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
;	:	O
massage	VB	O
gently	RB	O
until	IN	O
the	DT	O
medication	NN	O
disappears	VBZ	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
effected	VBN	O
eye	NN	O
up	RB	O
to	TO	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
(	(	O
1	CD	DOS
drop	NN	UNIT
covers	VBZ	O
an	DT	O
area	NN	O
of	IN	O
skin	$	O
2	CD	O
inches	NNS	O
by	IN	O
2	CD	O
inches	NNS	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
3	CD	O
-	:	O
4	CD	O
times	NNS	O
over	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
,	,	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
,	,	O
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
MYCOBUTIN	NNP	O
Capsules	NNP	O
be	VB	O
administered	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
300	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
two	CD	FREQ
to	TO	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Usual	JJ	O
Pediatric	NNP	whO
Dosage	NN	O
:	:	O
0.25	CD	DOS
to	TO	O
0.5	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	VBD	O
1	CD	FREQ
to	TO	O
4	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

PREMPRO	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
to	TO	O
be	VB	O
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
of	IN	O
enalapril	NN	O
is	VBZ	O
10	CD	DOS
to	TO	O
40	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

A	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
dose	NN	UNIT
of	IN	O
ACTHREL®	NNP	O
at	IN	O
1	CD	O
mcg	NN	O
/	NNP	O
kg	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
testing	NN	O
of	IN	O
pituitary	JJ	O
corticotrophin	NN	O
function	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
Diovan	NNP	O
HCT	NNP	O
160	CD	O
/	VBD	O
12.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Start	NNP	O
dosing	VBG	O
with	IN	O
45	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
1	CD	DOS
or	CC	O
2	CD	DOS
tablets	NNS	UNIT
(	(	O
25	CD	DOS
or	CC	O
50	CD	DOS
mg	NN	UNIT
)	)	O
4	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
preferably	RB	O
with	IN	O
meals	NNS	O
and	CC	O
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Actigall	NNP	O
treatment	NN	O
of	IN	O
radiolucent	JJ	O
gallbladder	NN	O
stones	NNS	O
is	VBZ	O
8	CD	DOS
-	:	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
2	CD	DOS
or	CC	O
3	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ADDYI	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
once	RB	FREQ
per	IN	FREQ
day	NN	FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
loading	NN	O
dose	NN	O
of	IN	O
SOMAVERT	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
given	VBN	O
subcutaneously	RB	O
,	,	O
under	IN	O
healthcare	NN	O
provider	NN	O
supervision	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	WHO
without	IN	WHO
congestive	JJ	WHO
heart	NN	WHO
failure	NN	WHO
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
or	CC	O
30	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
two	CD	DOS
inhalations	NNS	UNIT
(	(	O
400	CD	DOS
mcg	NN	UNIT
)	)	O
repeated	VBD	O
every	DT	FREQ
4	CD	FREQ
-	:	O
6	CD	FREQ
hours	NNS	FREQ
.	.	O

One	CD	DOS
tablet	NN	UNIT
three	CD	FREQ
or	CC	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Initiate	NNP	O
dosing	NN	O
at	IN	O
50	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
starting	VBG	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
BANZEL	NNP	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	O
Lennox	NNP	O
-	:	O
Gastaut	NNP	O
Syndrome	NNP	O
is	VBZ	O
approximately	RB	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
administered	VBN	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Vectibix	NNP	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
,	,	O
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
,	,	O
every	DT	FREQ
14	CD	FREQ
days	NNS	FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Topicort®	NNP	O
(	(	O
desoximetasone	NN	O
)	)	O
Ointment	NNP	O
USP	NNP	O
,	,	O
0.05	CD	O
%	NN	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
adult	NN	WHO
starting	VBG	O
dose	NN	O
is	VBZ	O
50	CD	DOS
to	TO	O
75	CD	DOS
mg	NN	UNIT
of	IN	O
the	DT	O
drug	NN	O
daily	RB	FREQ
,	,	O
together	RB	O
with	IN	O
1	CD	DOS
to	TO	O
4	CD	DOS
g	JJ	UNIT
daily	RB	FREQ
of	IN	O
a	DT	O
sulfonamide	NN	O
of	IN	O
the	DT	O
sulfapyrimidine	NN	O
type	NN	O
,	,	O
e.g	NN	O
.	.	O
sufadoxine	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
IMDUR	NNP	O
Tablets	NNP	O
is	VBZ	O
30	CD	DOS
mg	NN	UNIT
(	(	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
30	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
or	CC	O
as	IN	O
1	CD	O
/	$	O
2	CD	O
/	JJ	O
18	CD	O
of	IN	O
a	DT	O
60	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
)	)	O
or	CC	O
60	CD	DOS
mg	NN	UNIT
(	(	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
MENOPUR®	NNP	O
for	IN	O
women	NNS	O
who	WP	O
have	VBP	O
received	VBN	O
a	DT	O
GnRH	NNP	O
agonist	NN	O
for	IN	O
pituitary	JJ	O
suppression	NN	O
is	VBZ	O
225	CD	DOS
International	NNP	UNIT
Units	NNP	UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
XIFAXAN	NNP	O
is	VBZ	O
one	CD	DOS
200	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
3	CD	DUR
days	NNS	DUR
.	.	O

0.1	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
morning	NN	O
and	CC	O
bedtime	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
for	IN	O
1	CD	DUR
-	:	O
month	NN	DUR
administration	NN	O
,	,	O
incorporated	VBN	O
in	IN	O
a	DT	O
depot	NN	O
formulation	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
Trental	NNP	O
(	(	O
pentoxifylline	NN	O
)	)	O
is	VBZ	O
400	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
after	IN	O
meals	NNS	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
1000	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
given	VBN	O
as	IN	O
twice	RB	FREQ
-	:	O
daily	JJ	FREQ
dosing	NN	O
(	(	O
500	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
for	IN	O
ORBACTIV	NNP	O
is	VBZ	O
a	DT	O
single	JJ	DOS
1200	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
3	CD	O
hours	NNS	O
in	IN	O
patients	NNS	WHO
18	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

Adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
:	:	O
1	CD	DOS
to	TO	O
2	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
or	CC	O
as	IN	O
needed	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
dose	NN	O
of	IN	O
Fludarabine	NNP	O
Phosphate	NNP	O
Injection	NNP	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
diluted	VBD	O
in	IN	O
100	CD	DOS
to	TO	O
125	CD	DOS
cc	NN	UNIT
of	IN	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
USP	NNP	O
or	CC	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
USP	NNP	O
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
approximately	RB	O
30	CD	O
minutes	NNS	O
daily	RB	FREQ
for	IN	O
five	CD	DUR
consecutive	JJ	DUR
days	NNS	DUR
.	.	O

The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
ranges	VBZ	O
between	IN	O
3	CD	DOS
to	TO	O
6	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
:	:	O
One	CD	DOS
capsule	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
2	CD	DOS
capsules	NNS	UNIT
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
Children	NNP	WHO
over	IN	WHO
10	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
Usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	DOS
100	CD	DOS
mg	NN	UNIT
or	CC	O
200	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
as	IN	O
needed	VBN	O
for	IN	O
cough	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INFLECTRA	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
induction	NN	O
regimen	NNS	O
at	IN	O
0	CD	O
,	,	O
2	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
regimen	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
6	CD	FREQ
weeks	NNS	FREQ
thereafter	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
active	JJ	O
ankylosing	VBG	O
spondylitis	NN	O
.	.	O

10	CD	DOS
mL	NN	UNIT
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
6	CD	DOS
doses	NNS	UNIT
(	(	O
60	CD	DOS
mL	NN	UNIT
)	)	O
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
daily	RB	FREQ
dose	NN	O
of	IN	O
CEFOBID	NNP	O
(	(	O
sterile	JJ	O
cefoperazone	NN	O
)	)	O
is	VBZ	O
2	CD	DOS
to	TO	O
4	CD	DOS
grams	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
administered	VBN	O
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
administered	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
CELESTONE	NNP	O
Syrup	NNP	O
(	(	O
betamethasone	NN	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
0.6	CD	DOS
mg	NNS	UNIT
to	TO	O
7.2	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Desoximetasone	NNP	O
Ointment	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Initial	JJ	O
dosage	NN	O
of	IN	O
MIRADON	NNP	O
(	(	O
anisindione	NN	O
)	)	O
Tablets	NNPS	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
the	DT	O
first	JJ	O
day	NN	O
,	,	O
200	CD	DOS
mg	VBD	UNIT
the	DT	O
second	JJ	O
day	NN	O
,	,	O
and	CC	O
100	CD	DOS
mg	NN	UNIT
the	DT	O
third	JJ	O
day	NN	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
35	CD	DOS
to	TO	O
105	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
PANDEL	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
once	RB	FREQ
or	CC	O
twice	VB	FREQ
a	DT	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ZEPATIER	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DURLAZA	NNP	O
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
(	(	O
162.5	CD	DOS
mg	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
for	IN	O
systemic	JJ	O
and	CC	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
for	IN	O
average	NN	O
(	(	O
60	CD	O
kg	NN	O
)	)	O
adults	NNS	WHO
is	VBZ	O
3.1	CD	DOS
grams	NNS	UNIT
of	IN	O
TIMENTIN	NNP	O
(	(	O
3.1	CD	DOS
-	:	O
gram	NN	UNIT
vial	JJ	UNIT
containing	VBG	O
3	CD	DOS
grams	NNS	UNIT
ticarcillin	NN	O
and	CC	O
100	CD	DOS
mg	NN	UNIT
clavulanic	JJ	O
acid	NN	O
)	)	O
given	VBN	O
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
.	.	O

Initiate	NNP	O
therapy	NN	O
with	IN	O
HYSINGLA	NNP	O
ER	NNP	O
20	CD	DOS
mg	NN	UNIT
orally	RB	O
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
daily	JJ	FREQ
oral	JJ	O
dose	NN	O
of	IN	O
VIVLODEX	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
.	.	O

The	DT	O
recommended	JJ	O
MOVANTIK	NNP	O
dosage	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
22.5	CD	DOS
mg	NN	UNIT
for	IN	O
3	CD	DUR
-	:	O
month	NN	DUR
administration	NN	O
is	VBZ	O
one	CD	DOS
injection	NN	UNIT
every	DT	FREQ
12	CD	FREQ
weeks	NNS	FREQ
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
and	CC	O
maintenance	NN	O
dose	NN	O
of	IN	O
levatol®	NN	O
,	,	O
used	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antihypertensive	JJ	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
thiazide	JJ	O
-	:	O
type	NN	O
diuretics	NNS	O
,	,	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Adalat	NNP	O
CC	NNP	O
be	VB	O
administered	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
.	.	O

ADVAIR	NNP	O
HFA	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
2	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

WESTCORT	NNP	O
CREAM	NNP	O
(	(	O
hydrocortisone	NN	O
valerate	NN	O
cream	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
CERDELGA	NNP	O
is	VBZ	O
84	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
CYP2D6	NNP	O
EMs	NNP	O
and	CC	O
IMs	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dose	NN	O
of	IN	O
Cytotec	NNP	O
for	IN	O
reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
NSAID	NNP	O
-	:	O
induced	VBD	O
gastric	JJ	O
ulcers	NNS	O
is	VBZ	O
200	CD	DOS
mcg	NN	UNIT
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
with	IN	O
food	NN	O
.	.	O

Usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	DOS
capsules	NNS	UNIT
daily	RB	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Each	DT	O
MENVEO	NNP	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
intramuscular	JJ	O
injection	NN	UNIT
,	,	O
preferably	RB	O
into	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
in	IN	O
infants	NNS	O
or	CC	O
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
(	(	O
upper	JJ	O
arm	NN	O
)	)	O
in	IN	O
toddlers	NNS	O
,	,	O
adolescents	NNS	WHO
and	CC	WHO
adults	NNS	WHO
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
for	IN	O
TYGACIL	NNP	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
100	CD	DOS
mg	NN	UNIT
,	,	O
followed	VBN	O
by	IN	O
50	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initiation	NN	O
of	IN	O
INVEGA	NNP	O
SUSTENNA®	NNP	O
is	VBZ	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
234	CD	DOS
mg	NNS	UNIT
on	IN	O
treatment	NN	O
day	NN	O
1	CD	O
and	CC	O
156	CD	DOS
mg	NN	UNIT
one	CD	O
week	NN	O
later	RB	O
,	,	O
both	DT	O
administered	VBN	O
in	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
.	.	O

ASTEPRO	RB	O
0.1	CD	O
%	NN	O
,	,	O
1	CD	DOS
spray	NN	UNIT
per	IN	O
nostril	JJ	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

Use	NNP	O
once	RB	FREQ
or	CC	O
twice	VB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
up	IN	DUR
to	TO	DUR
7	CD	DUR
days	NNS	DUR
as	RB	O
needed	VBN	O
to	TO	O
relieve	VB	O
external	JJ	O
vulvar	NN	O
itching	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ZELBORAF	NNP	O
is	VBZ	O
960	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
240	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
orally	RB	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
with	IN	O
or	CC	O
without	IN	O
a	DT	O
meal	NN	O
.	.	O

Usual	JJ	O
dose	NN	O
:	:	O
Pyrazinamide	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
,	,	O
15	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
GENVOYA	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
food	NN	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
with	IN	WHO
body	NN	WHO
weight	NN	WHO
at	IN	WHO
least	JJS	WHO
35	CD	O
kg	NN	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
30	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
JARDIANCE	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
,	,	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
ANDRODERM	NNP	O
4	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
system	NN	O
(	(	O
not	RB	O
two	CD	DOS
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
systems	NNS	O
)	)	O
applied	VBD	O
nightly	RB	O
for	IN	O
24	CD	O
hours	NNS	O
,	,	O
delivering	VBG	O
approximately	RB	O
4	CD	DOS
mg	NNS	UNIT
of	IN	O
testosterone	NN	O
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Qutenza	NNP	O
is	VBZ	O
a	DT	O
single	JJ	DOS
,	,	O
60	CD	O
-	:	O
minute	NN	O
application	NN	O
of	IN	O
up	IN	O
to	TO	O
four	CD	O
patches	NNS	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
over	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
One	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
tablets	NNS	UNIT
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
8	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
a	DT	O
meal	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
TrophAmine	NNP	O
is	VBZ	O
2	CD	DOS
to	TO	O
2.5	CD	DOS
grams	NNS	UNIT
of	IN	O
amino	JJ	O
acids	NNS	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
(	(	O
2	CD	DOS
to	TO	O
2.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
for	IN	O
infants	NNS	WHO
up	RB	WHO
to	TO	WHO
10	CD	WHO
kilograms	NNS	WHO
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
REMERON	NNP	O
(	(	O
mirtazapine	NN	O
)	)	O
Tablets	NNPS	O
is	VBZ	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
evening	NN	O
prior	RB	O
to	TO	O
sleep	VB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Aveed	NNP	O
is	VBZ	O
3	CD	DOS
mL	NN	UNIT
(	(	O
750	CD	DOS
mg	NN	UNIT
)	)	O
injected	VBD	O
intramuscularly	RB	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	DOS
mL	NNS	UNIT
(	(	O
750	CD	DOS
mg	NN	UNIT
)	)	O
injected	VBD	O
after	IN	O
4	CD	O
weeks	NNS	O
,	,	O
then	RB	O
3	CD	DOS
mL	NNS	UNIT
(	(	O
750	CD	DOS
mg	NN	UNIT
)	)	O
injected	VBD	O
every	DT	FREQ
10	CD	FREQ
weeks	NNS	FREQ
thereafter	RB	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
studied	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
was	VBD	O
180	CD	DOS
mg	NN	UNIT
to	TO	O
480	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
with	IN	WHO
body	NN	WHO
weight	NN	WHO
at	IN	WHO
least	JJS	WHO
40	CD	WHO
kg	NN	WHO
(	(	O
at	IN	O
least	JJS	O
88	CD	O
lbs	NN	O
)	)	O
The	DT	O
dose	NN	O
of	IN	O
ATRIPLA	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
once	IN	FREQ
daily	JJ	FREQ
taken	VBN	O
orally	RB	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTEMRA	NNP	O
for	IN	O
adult	NN	WHO
patients	NNS	O
given	VBN	O
as	IN	O
a	DT	O
60	CD	DOS
-	:	O
minute	NN	O
single	JJ	O
intravenous	JJ	O
drip	NN	O
infusion	NN	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
followed	VBN	O
by	IN	O
an	DT	O
increase	NN	O
to	TO	O
8	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
.	.	O

One	CD	DOS
SITAVIG	NNP	O
50	CD	DOS
mg	NN	UNIT
buccal	JJ	UNIT
tablet	NN	UNIT
should	MD	O
be	VB	O
applied	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
to	TO	O
the	DT	O
upper	JJ	O
gum	NN	O
region	NN	O
(	(	O
canine	JJ	O
fossa	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Gadavist	NNP	O
for	IN	O
adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
(	(	O
including	VBG	O
term	NN	O
neonates	NNS	O
)	)	O
is	VBZ	O
0.1	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	NN	O
(	(	O
0.1	CD	O
mmol	NN	O
/	NNP	O
kg	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REMICADE	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
induction	NN	O
regimen	NNS	O
at	IN	O
0	CD	O
,	,	O
2	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
regimen	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
8	CD	FREQ
weeks	NNS	FREQ
thereafter	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adults	NNS	WHO
with	IN	WHO
moderately	RB	WHO
to	TO	WHO
severely	RB	WHO
active	JJ	WHO
Crohn	NNP	WHO
's	POS	WHO
disease	NN	WHO
or	CC	O
fistulizing	VBG	O
Crohn	NNP	O
's	POS	O
disease	NN	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
ALSUMA	NNP	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
injected	VBD	O
subcutaneously	RB	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
750	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
average	JJ	O
protective	JJ	O
dose	NN	O
of	IN	O
vitamin	NN	O
C	NNP	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
70	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
starting	NN	O
schedule	NN	O
for	IN	O
induction	NN	O
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
/	NN	O
m²administered	VBD	O
subcutaneously	RB	O
twice	JJ	FREQ
daily	RB	FREQ
for	IN	O
14	CD	DUR
consecutive	JJ	DUR
days	NNS	DUR
every	DT	FREQ
28	CD	FREQ
days	NNS	FREQ
,	,	O
over	IN	O
a	DT	O
28	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
1.34	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
/	RB	O
2	CD	DOS
/	JJ	O
18	CD	DOS
tablet	NN	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
EXONDYS	NNP	O
51	CD	O
is	VBZ	O
30	CD	DOS
milligrams	NNS	UNIT
per	IN	O
kilogram	NN	O
administered	VBN	O
once	RB	FREQ
weekly	JJ	FREQ
as	IN	O
a	DT	O
35	CD	O
to	TO	O
60	CD	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
12.5	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
given	VBN	O
once	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
IXEMPRA	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
3	CD	O
hours	NNS	O
every	DT	FREQ
3	CD	FREQ
weeks	NNS	FREQ
.	.	O

Recommended	VBN	O
starting	JJ	O
dosage	NN	O
is	VBZ	O
5	CD	DOS
mcg	JJ	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
at	IN	O
bedtime	NN	O
;	:	O
however	RB	O
,	,	O
some	DT	O
patients	NNS	O
may	MD	O
need	VB	O
a	DT	O
2	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
ADLYXIN	NNP	O
is	VBZ	O
10	CD	DOS
mcg	NN	UNIT
subcutaneously	RB	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
14	CD	DUR
days	NNS	DUR
.	.	O

Usual	JJ	O
Adult	NNP	WHO
Dose	NNP	O
:	:	O
One	CD	DOS
teaspoonful	NN	UNIT
(	(	O
5	CD	DOS
mL	NN	UNIT
)	)	O
after	IN	O
meals	NNS	O
and	CC	O
at	IN	O
bedtime	NN	O
,	,	O
not	RB	O
less	JJR	O
than	IN	O
4	CD	O
hours	NNS	O
apart	RB	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
6	CD	DOS
teaspoonfuls	NNS	UNIT
in	IN	O
a	DT	O
24	CD	O
hour	NN	O
period	NN	O
)	)	O
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
NASAREL	NNP	O
is	VBZ	O
2	CD	DOS
sprays	NNS	UNIT
(	(	O
58	CD	DOS
mcg	NN	UNIT
)	)	O
in	IN	O
each	DT	O
nostril	NN	O
2	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
(	(	O
total	JJ	O
dose	RB	O
232	CD	DOS
mcg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
)	)	O
:	:	O
the	DT	O
effect	NN	O
should	MD	O
be	VB	O
assessed	VBN	O
in	IN	O
4	CD	DUR
to	TO	DUR
7	CD	DUR
days	NNS	DUR
.	.	O

KYBELLA	NNP	O
is	VBZ	O
injected	VBN	O
into	IN	O
subcutaneous	JJ	O
fat	JJ	O
tissue	NN	O
in	IN	O
the	DT	O
submental	JJ	O
area	NN	O
using	VBG	O
an	DT	O
area	NN	O
-	:	O
adjusted	VBN	O
dose	NN	O
of	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
cm²	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Kineret	NNP	O
is	VBZ	O
1	CD	DOS
-	:	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
for	IN	O
NOMID	NNP	WHO
patients	NNS	WHO
.	.	O

A	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Cormax	NNP	O
Ointment	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
with	IN	O
gentle	JJ	O
rubbing	VBG	O
to	TO	O
the	DT	O
affected	JJ	O
skin	JJ	O
area	NN	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
once	RB	O
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
once	RB	O
at	IN	O
night	NN	O
.	.	O

IFEX	NNP	O
(	(	O
ifosfamide	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1.2	CD	DOS
g	NNS	UNIT
/	JJ	O
m²	JJ	O
per	IN	FREQ
day	NN	FREQ
for	IN	O
5	CD	DUR
consecutive	JJ	DUR
days	NNS	DUR
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PROVIGIL	NNP	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
narcolepsy	JJ	WHO
or	CC	WHO
OSA	NNP	WHO
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IMBRUVICA	NNP	O
for	IN	O
MCL	NNP	O
is	VBZ	O
560	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
140	CD	DOS
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
RETROVIR	NNP	O
is	VBZ	O
300	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

Donnatal®	NNP	O
Tablets	NNP	O
-	:	O
Adults	NNS	O
:	:	O
One	CD	DOS
or	CC	O
two	CD	DOS
Donnatal®	NNP	UNIT
Tablets	NNPS	UNIT
three	CD	FREQ
or	CC	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
according	VBG	O
to	TO	O
condition	NN	O
and	CC	O
severity	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

Administer	NNP	O
CYMBALTA	NNP	O
at	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
given	VBN	O
as	IN	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
to	TO	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
given	VBN	O
either	DT	O
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
as	IN	O
30	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PLETAL	NNP	O
is	VBZ	O
100	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
taken	VBN	O
at	IN	O
least	JJS	O
half	PDT	O
an	DT	O
hour	NN	O
before	IN	O
or	CC	O
two	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
.	.	O

Administer	RB	O
ABLAVAR	NNP	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
,	,	O
manually	RB	O
or	CC	O
by	IN	O
power	NN	O
injection	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.12	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
(	(	O
0.03	CD	O
mmol	NN	O
/	NNP	O
kg	NN	O
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
up	IN	O
to	TO	O
30	CD	O
seconds	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
25	CD	DOS
-	:	O
30	CD	DOS
mL	NN	UNIT
normal	JJ	O
saline	JJ	O
flush	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
OPDIVO	NNP	O
is	VBZ	O
240	CD	DOS
mg	NN	UNIT
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
COLCRYS	NNP	O
for	IN	O
prophylaxis	NN	O
of	IN	O
gout	NN	O
flares	NNS	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
older	JJR	WHO
than	IN	WHO
16	CD	HO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
0.6	CD	DOS
mg	NN	UNIT
once	RB	FREQ
or	CC	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

One	CD	DOS
drop	NN	UNIT
of	IN	O
ILEVRO	NNP	O
(	(	O
nepafenac	JJ	O
ophthalmic	JJ	O
suspension	NN	O
)	)	O
,	,	O
0.3	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
one	CD	FREQ
-	:	O
time	NN	FREQ
-	:	O
daily	JJ	FREQ
beginning	VBG	O
1	CD	O
day	NN	O
prior	RB	O
to	TO	O
cataract	VB	O
surgery	NN	O
,	,	O
continued	VBD	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
and	CC	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Endometrin	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
vaginally	RB	O
two	CD	O
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
starting	VBG	O
the	DT	O
day	NN	O
after	IN	O
oocyte	JJ	O
retrieval	NN	O
and	CC	O
continuing	VBG	O
for	IN	O
up	IN	DUR
to	TO	DUR
10	CD	DUR
weeks	NNS	DUR
total	JJ	O
duration	NN	O
.	.	O

The	DT	O
recommended	JJ	O
bolus	NN	O
dose	NN	O
for	IN	O
activated	JJ	O
DEFINITY	NNP	O
is	VBZ	O
10	CD	DOS
microliters	NNS	UNIT
(	(	O
microL	NN	O
)	)	O
/	VBZ	O
kg	NN	O
of	IN	O
the	DT	O
activated	JJ	O
product	NN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
within	IN	O
30	CD	O
-	:	O
60	CD	O
seconds	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10	CD	DOS
mL	NN	UNIT
saline	NN	O
flush	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BIVIGAM	NNP	O
for	IN	O
replacement	NN	O
therapy	NN	O
in	IN	O
primary	JJ	O
humoral	JJ	O
immunodeficiency	NN	O
(	(	O
PI	NNP	O
)	)	O
is	VBZ	O
300	CD	DOS
to	TO	O
800	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
administered	VBN	O
every	DT	FREQ
3	CD	FREQ
to	TO	O
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Duraclon	NNP	O
for	IN	O
continuous	JJ	O
epidural	JJ	O
infusion	NN	O
is	VBZ	O
30	CD	DOS
mcg	NN	UNIT
/	NNP	FREQ
hr	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
both	DT	O
adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
1	CD	DOS
single	JJ	DOS
-	:	O
use	NN	DOS
ampule	NN	UNIT
(	(	O
300	CD	DOS
mg	NN	UNIT
)	)	O
administered	VBD	O
BID	NNP	O
for	IN	O
28	CD	DUR
days	NNS	DUR
.	.	O

Initial	JJ	O
200	CD	DOS
-	:	O
400	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
,	,	O
with	IN	O
meals	NNS	O
or	CC	O
milk	NN	O
,	,	O
gradually	RB	O
increasing	VBG	O
when	WRB	O
necessary	JJ	O
to	TO	O
full	JJ	O
maintenance	NN	O
dosage	NN	O
in	IN	O
one	CD	O
week	NN	O
.	.	O

Adacel	NNP	O
vaccine	NN	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
intramuscular	JJ	O
injection	NN	UNIT
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

The	DT	O
recommended	VBN	O
initial	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
FOSRENOL	NNP	O
is	VBZ	O
1500	CD	DOS
mg	NN	UNIT
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dosage	NN	O
for	IN	O
duodenal	JJ	O
ulcer	NN	O
is	VBZ	O
1	CD	DOS
g	NN	UNIT
(	(	O
10	CD	DOS
mL	NN	UNIT
/	VBD	O
2	CD	DOS
teaspoons	NNS	UNIT
)	)	O
four	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
TIMOPTIC	NNP	O
-	:	O
XE	NN	O
(	(	O
either	CC	O
0.25	CD	O
%	NN	O
or	CC	O
0.5	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dosage	NN	O
of	IN	O
ZOFRAN	NNP	O
is	VBZ	O
24	CD	DOS
mg	NN	UNIT
given	VBN	O
as	IN	O
three	CD	DOS
8	CD	DOS
-	:	O
mg	NN	UNIT
tablets	NNS	UNIT
administered	VBD	O
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
single	JJ	O
-	:	O
day	NN	O
highly	RB	O
emetogenic	JJ	O
chemotherapy	NN	O
,	,	O
including	VBG	O
cisplatin	NN	O
≥	VBD	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
m	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Gammaplex	NNP	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
PI	NNP	WHO
is	VBZ	O
300	CD	DOS
to	TO	O
800	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
6	CD	DOS
to	TO	O
16	CD	DOS
mL	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
,	,	O
administered	VBN	O
every	DT	FREQ
3	CD	FREQ
to	TO	O
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
1	CD	DOS
to	TO	O
3	CD	DOS
mg	NNS	UNIT
administered	VBN	O
under	IN	O
careful	JJ	O
monitoring	NN	O
,	,	O
such	JJ	O
as	IN	O
electrocardiography	NN	O
and	CC	O
central	JJ	O
venous	JJ	O
pressure	NN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
0.1	CD	O
%	NN	O
HALOG	NNP	O
OINTMENT	NNP	O
(	(	O
Halcinonide	NNP	O
Ointment	NNP	O
,	,	O
USP	NNP	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
two	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Most	JJS	WHO
patients	NNS	WHO
require	VBP	O
60	CD	DOS
to	TO	O
120	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
one	CD	DOS
0.1	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
at	IN	O
bedtime	NN	O
.	.	O

Buprenorphine	NNP	O
and	CC	O
naloxone	RB	O
sublingual	JJ	O
tablets	NNS	O
are	VBP	O
administered	VBN	O
sublingually	RB	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

RISPERDAL®	NNP	O
CONSTA®	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
by	IN	O
deep	JJ	O
intramuscular	NN	O
(	(	O
IM	NNP	O
)	)	O
deltoid	NN	O
or	CC	O
gluteal	JJ	O
injection	NN	O
.	.	O

GEODON	NNP	O
Capsules	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
VINCASAR	NNP	O
PFS	NNP	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
1.4	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
GYNAZOLE•1®	NNP	O
Butoconazole	NNP	O
Nitrate	NNP	O
Vaginal	NNP	O
Cream	NNP	O
USP	NNP	O
,	,	O
2	CD	O
%	NN	O
is	VBZ	O
one	CD	DOS
applicatorful	NN	UNIT
of	IN	O
cream	NN	O
(	(	O
approximately	RB	O
5	CD	DOS
grams	NNS	UNIT
of	IN	O
the	DT	O
cream	NN	O
)	)	O
intravaginally	RB	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
dose	NN	O
for	IN	O
initial	JJ	O
nasal	JJ	O
administration	NN	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
spray	NN	UNIT
in	IN	O
one	CD	O
nostril	NN	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
treatment	NN	O
regimen	NNS	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
VIRAZOLE	NNP	O
(	(	O
ribavirin	NN	O
)	)	O
as	IN	O
the	DT	O
starting	VBG	O
solution	NN	O
in	IN	O
the	DT	O
drug	NN	O
reservoir	NN	O
of	IN	O
the	DT	O
SPAG	NNP	O
-	:	O
2	CD	DOS
unit	NN	UNIT
,	,	O
with	IN	O
continuous	JJ	O
aerosol	NNS	O
administration	NN	O
for	IN	O
12	CD	O
-	:	O
18	CD	O
hours	NNS	O
per	IN	FREQ
day	NN	FREQ
for	IN	O
3	CD	DUR
to	TO	O
7	CD	DUR
days	NNS	DUR
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
dose	NN	O
,	,	O
after	IN	O
reconstitution	NN	O
with	IN	O
oxidant	JJ	O
-	:	O
free	JJ	O
sodium	NN	O
pertechnetate	NN	O
Tc	NNP	O
99m	CD	O
,	,	O
is	VBZ	O
370	CD	DOS
to	TO	O
740	CD	DOS
megabecquerels	NNS	UNIT
(	(	O
10	CD	DOS
to	TO	O
20	CD	DOS
millicuries	NNS	UNIT
[	VBP	O
200	CD	DOS
μCi	JJ	UNIT
/	NNP	O
kg	NNP	O
]	NNP	O
)	)	O
by	IN	O
slow	JJ	O
intravenous	JJ	O
injection	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
30	CD	O
seconds	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dietary	JJ	O
potassium	NN	O
intake	NN	O
by	IN	O
the	DT	O
average	JJ	O
adult	NN	WHO
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mEq	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
vasomotor	NN	O
symptoms	NNS	O
or	CC	O
moderate	VB	O
to	TO	O
severe	VB	O
symptoms	NNS	O
of	IN	O
vulvar	NN	O
and	CC	O
vaginal	JJ	O
atrophy	NN	O
associated	VBN	O
with	IN	O
the	DT	O
menopause	NN	O
,	,	O
initiate	JJ	O
therapy	NN	O
with	IN	O
Estraderm	NNP	O
(	(	O
estradiol	FW	O
transdermal	NN	O
)	)	O
0.05	CD	O
applied	VBN	O
to	TO	O
the	DT	O
skin	NN	O
twice	RB	FREQ
weekly	RB	FREQ
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
is	VBZ	O
generally	RB	O
taken	VBN	O
at	IN	O
a	DT	O
single	JJ	O
time	NN	O
each	DT	O
morning	NN	O
with	IN	O
breakfast	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
intravenous	JJ	O
dosage	NN	O
of	IN	O
ZOFRAN	NNP	O
is	VBZ	O
three	CD	DOS
0.15	CD	DOS
-	:	O
mg	NN	UNIT
/	JJ	O
kg	NN	O
doses	VBZ	O
up	RP	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	DOS
mg	NNS	UNIT
per	IN	O
dose	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
2	CD	DOS
caplets	NNS	UNIT
three	CD	FREQ
or	CC	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
BRISDELLE	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
VMS	NNP	O
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
,	,	O
at	IN	O
bedtime	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

One	CD	DOS
tablet	NN	UNIT
is	VBZ	O
taken	VBN	O
every	DT	FREQ
day	NN	FREQ
,	,	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
RYTARY	NNP	O
in	IN	O
levodopa	JJ	O
-	:	O
naïve	NN	WHO
patients	NNS	WHO
is	VBZ	O
23.75	CD	DOS
mg	NN	UNIT
/	VBD	O
95	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
days	NNS	O
.	.	O

Dose	NNP	O
once	RB	FREQ
-	:	O
daily	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
6.25	CD	DOS
mg	NN	UNIT
for	IN	O
women	NNS	WHO
and	CC	O
either	DT	O
6.25	CD	DOS
or	CC	O
12.5	CD	DOS
mg	NN	UNIT
for	IN	O
men	NNS	WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	FREQ
per	IN	FREQ
night	NN	FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7	CD	O
-	:	O
8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Calcium	NNP	O
Disodium	NNP	O
Versenate	NNP	O
for	IN	O
asymptomatic	JJ	O
adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
whose	WP$	WHO
blood	JJ	WHO
lead	NN	WHO
level	NN	WHO
is	VBZ	WHO
<	JJ	O
70	CD	O
mcg	NN	O
/	NN	O
dl	NN	O
but	CC	O
>	$	O
20	CD	DOS
mcg	NN	UNIT
/	NN	O
dl	NN	O
(	(	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
recommended	VBD	O
upper	JJ	O
allowable	JJ	O
level	NN	O
)	)	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
/	NNP	FREQ
day	NN	FREQ
whether	IN	O
given	VBN	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
COLESTID	NNP	O
Tablets	NNP	O
are	VBP	O
recommended	VBN	O
in	IN	O
doses	NNS	O
of	IN	O
2	CD	DOS
to	TO	O
16	CD	DOS
grams	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
given	VBN	O
once	RB	O
or	CC	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
dose	JJ	O
range	NN	O
for	IN	O
LIVALO	NNP	O
is	VBZ	O
1	CD	DOS
to	TO	O
4	CD	DOS
mg	NNS	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
any	DT	O
time	NN	O
of	IN	O
the	DT	O
day	NN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

For	IN	O
the	DT	O
clinical	JJ	O
dietary	JJ	O
management	NN	O
of	IN	O
the	DT	O
metabolic	JJ	O
processes	NNS	O
of	IN	O
OA	NNP	O
,	,	O
take	VBP	O
either	DT	O
one	CD	DOS
250	CD	DOS
mg	NN	UNIT
or	CC	O
one	CD	DOS
500	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
for	IN	O
500	CD	DOS
mg	NN	UNIT
to	TO	O
1000	CD	DOS
mg	NN	UNIT
total	JJ	O
daily	JJ	FREQ
consumption	NN	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
antihypertensive	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
NORVASC	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
,	,	O
and	CC	O
the	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
GILOTRIF	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
orally	RB	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
no	DT	O
longer	RB	O
tolerated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
80	CD	DOS
mg	JJ	UNIT
Inderal	NNP	O
LA	NNP	O
once	RB	FREQ
daily	RB	FREQ
,	,	O
whether	IN	O
used	VBN	O
alone	RB	O
or	CC	O
added	VBN	O
to	TO	O
a	DT	O
diuretic	JJ	O
.	.	O

